연구동향 분석

종설 : 염증성장질환에서 대장암의 약물적 예방

한승희 ( Sung Hee Han ) 이종훈 ( Jong Hun Lee ) 2014년

논문상세정보
인용/피인용
' 종설 : 염증성장질환에서 대장암의 약물적 예방' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • chemoprevention
  • colorectal neoplasms
  • inflammatory bowel diseases
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
358 0

0.0%

' 종설 : 염증성장질환에서 대장암의 약물적 예방' 의 참고문헌

  • Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis
    Tung BY Ann Intern Med 134 : 89 ~ 95 - [2001]
  • Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease : a metaanalysis
    Hansen JD Dig Dis Sci 58 : 3079 ~ 3087 - [2013]
  • Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis
    Pardi DS Gastroenterology 124 : 889 ~ 893 - [2003]
  • Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease
    van Schaik FD Gut 61 : 235 ~ 240 [2012]
  • The role of aspirin in cancer prevention
    Thun MJ Nat Rev Clin Oncol 9 : 259 ~ 267 - [2012]
  • The role of COX-2 in intestinal inflammation and colorectal cancer
    Wang D Oncogene 29 : 781 ~ 788 - [2010]
  • The risk of inflammatory bowel disease-related colorectal carcinoma is limited : results from a nationwide nested case-control study
    Baars JE Am J Gastroenterol 106 : 319 ~ 328 - [2011]
  • The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis
    Shetty K Am J Gastroenterol 94 : 1643 ~ 1649 - [1999]
  • The new prophylactic strategy for colon cancer in inflammatory bowel disease by modulating microbiota
    Kanauchi O Scand J Gastroenterol 48 : 387 ~ 400 - [2013]
  • The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis
    Wolf JM Aliment Pharmacol Ther 22 : 783 ~ 788 - [2005]
  • The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis
    Lashner BA Gastroenterology 112 : 29 ~ 32 - [1997]
  • Statins and the risk of colorectal cancer
    Poynter JN N Engl J Med 352 : 2184 ~ 2192 - [2005]
  • Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study
    Broughton T BMC Gastroenterol 12 : 36 ~ - [2012]
  • Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
    Rutter M Gastroenterology 126 : 451 ~ 459 - [2004]
  • Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use
    Samadder NJ Cancer 117 : 1640 ~ 1648 - [2011]
  • Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis
    Braden B Clin Gastroenterol Hepatol 10 : 303 ~ 308 [2012]
  • Risk factors of colorectal cancer in inflammatory bowel disease
    Bansal P Am J Gastroenterol 91 : 44 ~ 48 - [1996]
  • Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota
    Jess T Am J Gastroenterol 102 : 829 ~ 836 - [2007]
  • Risk factors for colorectal cancer in patients with ulcerative colitis : a case-control study
    Pinczowski D Gastroenterology 107 : 117 ~ 120 - [1994]
  • Risk factors for colorectal cancer in Crohn's colitis : a case-control study
    Siegel CA Inflamm Bowel Dis 12 : 491 ~ 496 - [2006]
  • Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease
    Allgayer H Aliment Pharmacol Ther 18 (2) : 10 ~ 14 - [2003]
  • Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs
    Carson, D. A. Corr, M. Cottam, H. B. Lu D Proc Natl Acad Sci U S A 102 : 18567 ~ 18571 - [2005]
  • Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk
    Simon MS Ann Epidemiol 22 : 17 ~ 27 - [2012]
  • Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine
    Ullman T Clin Gastroenterol Hepatol 6 : 1225 ~ 1230 - [2008]
  • Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study
    Velayos FS Gastroenterology 130 : 1941 ~ 1949 - [2006]
  • PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    Shepherd J Lancet 360 : 1623 ~ 1630 - [2002]
  • Multi-target approaches in colon cancer chemoprevention based on systems biology of tumor cellsignaling
    Guruswamy S Gene Regul Syst Bio 2 : 163 ~ 176 [2008]
  • Molecular basis of the potential of mesalazine to prevent colorectal cancer
    Stolfi C World J Gastroenterol 14 : 4434 ~ 4439 - [2008]
  • Micronutrient deficiencies in inflammatory bowel disease: from A to zinc
    Hwang C Inflamm Bowel Dis 18 : 1961 ~ 1981 - [2012]
  • Mesalamine protects against colorectal cancer in inflammatory bowel disease
    Tang J Dig Dis Sci 55 : 1696 ~ 1703 - [2010]
  • Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease
    O'Connor PM Inflamm Bowel Dis 16 : 1411 ~ 1420 - [2010]
  • Matrix metalloproteinase- 9 functional promoter polymorphism 1562C >T increased risk of early-onset coronary artery disease
    Saedi M Mol Biol Rep 39 : 555 ~ 562 - [2012]
  • Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
    Fraser AG Aliment Pharmacol Ther 16 : 1225 ~ 1232 - [2002]
  • Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
    Connell WR Lancet 343 : 1249 ~ 1252 - [1994]
  • Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow- up of five randomised trials
    Rothwell PM Lancet 376 : 1741 ~ 1750 - [2010]
  • IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry
    Seufert BL Carcinogenesis 34 : 79 ~ 85 - [2013]
  • Inflammatory bowel disease in Asia: a systematic review
    Prideaux L J Gastroenterol Hepatol 27 : 1266 ~ 1280 - [2012]
  • Inflammation and colorectal cancer : IBD-associated and sporadic cancer compared
    Rhodes JM Trends Mol Med 8 : 10 ~ 16 - [2002]
  • Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    Kandiel A Gut 54 : 1121 ~ 1125 - [2005]
  • Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis : a meta-analysis
    Soetikno RM Gastrointest Endosc 56 : 48 ~ 54 - [2002]
  • Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease
    Long MD Clin Gastroenterol Hepatol 8 : 268 ~ 274 - [2010]
  • In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment
    Rudolph G Dig Dis Sci 56 : 3624 ~ 3630 - [2011]
  • Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study
    Gupta RB Gastroenterology 133 : 1099 ~ 1105 - [2007]
  • High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis
    Eaton JE Am J Gastroenterol 106 : 1638 ~ 1645 - [2011]
  • High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study
    Olsson R Gastroenterology 129 : 1464 ~ 1472 - [2005]
  • High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia
    Lindström L Aliment Pharmacol Ther 35 : 451 ~ 457 [2012]
  • Genetic variation in 3-hydroxy- 3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer
    Lipkin SM Cancer Prev Res (Phila) 3 : 597 ~ 603 - [2010]
  • Folic acid and prevention of colorectal adenomas: a combined analysis of randomized clinical trials
    Figueiredo JC Int J Cancer 129 : 192 ~ 203 - [2011]
  • Folate deprivation enhances invasiveness of human colon cancer cells mediated by activation of sonic hedgehog signaling through promoter hypomethylation and cross action with transcription nuclear factor- kappa B pathway
    Wang TP Carcinogenesis 33 : 1158 ~ 1168 - [2012]
  • Etiopathogenesis of inflammatory bowel diseases
    Danese S World J Gastroenterol 12 : 4807 ~ 4812 - [2006]
  • Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study
    Lashner BA Gastroenterology 97 : 255 ~ 259 - [1989]
  • Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
    Rothwell PM Lancet 377 : 31 ~ 41 - [2011]
  • Effect of combined folic acid, vitamin B(6), and vitamin B(12) on colorectal adenoma
    Song Y J Natl Cancer Inst 104 : 1562 ~ 1575 - [2012]
  • Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies
    Velayos FS Am J Gastroenterol 100 : 1345 ~ 1353 - [2005]
  • Crossroad between inflammation and carcinogenesis in colon
    Yeo M Korean J Med 70 : 130 ~ 137 [2006]
  • Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells
    Xiao H Int J Cancer 122 : 2115 ~ 2124 - [2008]
  • Colorectal cancer prognosis among patients with inflammatory bowel disease
    Delaunoit T Clin Gastroenterol Hepatol 4 : 335 ~ 342 - [2006]
  • Colorectal cancer prevention in ulcerative colitis : a case-control study
    Eaden J Aliment Pharmacol Ther 14 : 145 ~ 153 - [2000]
  • Cocoa polyphenols prevent inflammation in the colon of azoxymethanetreated rats and in TNF-α-stimulated Caco-2 cells
    Rodríguez-Ramiro I Br J Nutr 110 : 206 ~ 215 - [2013]
  • Chemoprevention of colorectal neoplasia in ulcerative colitis : the effect of 6-mercaptopurine
    Matula S Clin Gastroenterol Hepatol 3 : 1015 ~ 1021 - [2005]
  • Cancer prevention by targeting angiogenesis
    Albini A Nat Rev Clin Oncol 9 : 498 ~ 509 [2012]
  • British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)
    Cairns SR Gut 59 : 666 ~ 689 - [2010]
  • Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression
    Sinakos E Hepatology 52 : 197 ~ 203 - [2010]
  • B-Vitamin Treatment Trialists' Collaboration. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals
    Vollset SE Lancet 381 : 1029 ~ 1036 - [2013]
  • Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease
    Sandborn W Cochrane Database Syst Rev : CD000545 ~ [2000]
  • Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis
    Pearson DC Ann Intern Med 123 : 132 ~ 142 - [1995]
  • Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies
    Liu Y Cancer Causes Control [2013]
  • Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis
    Rubin DT Clin Gastroenterol Hepatol 4 : 1346 ~ 1350 - [2006]
  • American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis
    Chapman R Hepatology 51 : 660 ~ 678 - [2010]
  • AGA Institute Medical Position Panel on Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease
    Farraye FA Gastroenterology 138 : 738 ~ 745 [2010]
  • 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations
    Nguyen GC Am J Gastroenterol 107 : 1298 ~ 1304 - [2012]
  • 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study
    Bernstein CN Am J Gastroenterol 106 : 731 ~ 736 - [2011]
  • 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease
    Terdiman JP Inflamm Bowel Dis 13 : 367 ~ 371 - [2007]
  • 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease : a large epidemiological study
    van Staa TP Gut 54 : 1573 ~ 1578 [2005]